INTEGRATED BIOPHARMA INC Net Income Loss

• INTEGRATED BIOPHARMA INC showed an increase of +621.4% in Net Income Loss from 2024 to 2025.
• This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), INTEGRATED BIOPHARMA INC's Net Income Loss has grown by 135.4%.
• Historical annual values: Fiscal year 2025: $808.0 thousand | Fiscal year 2024: $112.0 thousand | Fiscal year 2023: -$34.0 thousand | Fiscal year 2022: $3.84 million | Fiscal year 2021: $8.01 million | Fiscal year 2020: $4.11 million | Fiscal year 2019: $1.69 million | Fiscal year 2018: $679.0 thousand | Fiscal year 2017: $2.35 million | Fiscal year 2016: $958.0 thousand | Fiscal year 2015: $735.0 thousand | Fiscal year 2014: $131.0 thousand | Fiscal year 2013: $93.0 thousand | Fiscal year 2012: -$2.71 million | Fiscal year 2011: -$2.28 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026